Employing nanoliposomal delivery [217] and osmotic minipumps for drug delivery [218] and developing PCa-specific antibody-drug conjugates to deliver ALDH inhibitors can potentially advance the ALDH-targeted therapy [219] and make it more specific for tumor tissues. Here, LDHA is linked to neoplasm.